305 related articles for article (PubMed ID: 22825365)
1. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.
Leffler DA; Kelly CP; Abdallah HZ; Colatrella AM; Harris LA; Leon F; Arterburn LA; Paterson BM; Lan ZH; Murray JA
Am J Gastroenterol; 2012 Oct; 107(10):1554-62. PubMed ID: 22825365
[TBL] [Abstract][Full Text] [Related]
2. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.
Kelly CP; Green PH; Murray JA; Dimarino A; Colatrella A; Leffler DA; Alexander T; Arsenescu R; Leon F; Jiang JG; Arterburn LA; Paterson BM; Fedorak RN;
Aliment Pharmacol Ther; 2013 Jan; 37(2):252-62. PubMed ID: 23163616
[TBL] [Abstract][Full Text] [Related]
3. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.
Leffler DA; Kelly CP; Green PH; Fedorak RN; DiMarino A; Perrow W; Rasmussen H; Wang C; Bercik P; Bachir NM; Murray JA
Gastroenterology; 2015 Jun; 148(7):1311-9.e6. PubMed ID: 25683116
[TBL] [Abstract][Full Text] [Related]
4. Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials.
Hoilat GJ; Altowairqi AK; Ayas MF; Alhaddab NT; Alnujaidi RA; Alharbi HA; Alyahyawi N; Kamal A; Alhabeeb H; Albazee E; Almustanyir S; Abu-Zaid A
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101782. PubMed ID: 34339872
[TBL] [Abstract][Full Text] [Related]
5. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo.
Gopalakrishnan S; Durai M; Kitchens K; Tamiz AP; Somerville R; Ginski M; Paterson BM; Murray JA; Verdu EF; Alkan SS; Pandey NB
Peptides; 2012 May; 35(1):86-94. PubMed ID: 22401908
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M
Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096
[TBL] [Abstract][Full Text] [Related]
7. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate.
Khaleghi S; Ju JM; Lamba A; Murray JA
Therap Adv Gastroenterol; 2016 Jan; 9(1):37-49. PubMed ID: 26770266
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D; Mäki M; Lundin KEA; Isola J; Friesing-Sosnik T; Taavela J; Popp A; Koskenpato J; Langhorst J; Hovde Ø; Lähdeaho ML; Fusco S; Schumann M; Török HP; Kupcinskas J; Zopf Y; Lohse AW; Scheinin M; Kull K; Biedermann L; Byrnes V; Stallmach A; Jahnsen J; Zeitz J; Mohrbacher R; Greinwald R;
N Engl J Med; 2021 Jul; 385(1):35-45. PubMed ID: 34192430
[TBL] [Abstract][Full Text] [Related]
9. Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments.
Valitutti F; Fasano A
Dig Dis Sci; 2019 Jul; 64(7):1748-1758. PubMed ID: 31076989
[TBL] [Abstract][Full Text] [Related]
10. No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.
Murray JA; Kelly CP; Green PHR; Marcantonio A; Wu TT; Mäki M; Adelman DC;
Gastroenterology; 2017 Mar; 152(4):787-798.e2. PubMed ID: 27864127
[TBL] [Abstract][Full Text] [Related]
11. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study.
Tack GJ; van de Water JM; Bruins MJ; Kooy-Winkelaar EM; van Bergen J; Bonnet P; Vreugdenhil AC; Korponay-Szabo I; Edens L; von Blomberg BM; Schreurs MW; Mulder CJ; Koning F
World J Gastroenterol; 2013 Sep; 19(35):5837-47. PubMed ID: 24124328
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the Presence of Non-Celiac Gluten Sensitivity in Patients with Functional Gastrointestinal Symptoms: Results from a Multicenter Randomized Double-Blind Placebo-Controlled Gluten Challenge.
Elli L; Tomba C; Branchi F; Roncoroni L; Lombardo V; Bardella MT; Ferretti F; Conte D; Valiante F; Fini L; Forti E; Cannizzaro R; Maiero S; Londoni C; Lauri A; Fornaciari G; Lenoci N; Spagnuolo R; Basilisco G; Somalvico F; Borgatta B; Leandro G; Segato S; Barisani D; Morreale G; Buscarini E
Nutrients; 2016 Feb; 8(2):84. PubMed ID: 26867199
[TBL] [Abstract][Full Text] [Related]
13. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
Lähdeaho ML; Kaukinen K; Laurila K; Vuotikka P; Koivurova OP; Kärjä-Lahdensuu T; Marcantonio A; Adelman DC; Mäki M
Gastroenterology; 2014 Jun; 146(7):1649-58. PubMed ID: 24583059
[TBL] [Abstract][Full Text] [Related]
14. Current pharmacological approaches and potential future therapies for Celiac disease.
Kulkarni A; Patel S; Khanna D; Parmar MS
Eur J Pharmacol; 2021 Oct; 909():174434. PubMed ID: 34418405
[TBL] [Abstract][Full Text] [Related]
15. Larazotide acetate promotes tight junction assembly in epithelial cells.
Gopalakrishnan S; Tripathi A; Tamiz AP; Alkan SS; Pandey NB
Peptides; 2012 May; 35(1):95-101. PubMed ID: 22401910
[TBL] [Abstract][Full Text] [Related]
16. Celiac disease 2015 update: new therapies.
Veeraraghavan G; Leffler DA; Kaswala DH; Mukherjee R
Expert Rev Gastroenterol Hepatol; 2015 Jul; 9(7):913-27. PubMed ID: 25864708
[TBL] [Abstract][Full Text] [Related]
17. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial.
Biesiekierski JR; Newnham ED; Irving PM; Barrett JS; Haines M; Doecke JD; Shepherd SJ; Muir JG; Gibson PR
Am J Gastroenterol; 2011 Mar; 106(3):508-14; quiz 515. PubMed ID: 21224837
[TBL] [Abstract][Full Text] [Related]
18. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Daveson AJM; Ee HC; Andrews JM; King T; Goldstein KE; Dzuris JL; MacDougall JA; Williams LJ; Treohan A; Cooreman MP; Anderson RP
EBioMedicine; 2017 Dec; 26():78-90. PubMed ID: 29191561
[TBL] [Abstract][Full Text] [Related]
19. Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity.
Skodje GI; Sarna VK; Minelle IH; Rolfsen KL; Muir JG; Gibson PR; Veierød MB; Henriksen C; Lundin KEA
Gastroenterology; 2018 Feb; 154(3):529-539.e2. PubMed ID: 29102613
[TBL] [Abstract][Full Text] [Related]
20. Larazotide acetate: a pharmacological peptide approach to tight junction regulation.
Slifer ZM; Krishnan BR; Madan J; Blikslager AT
Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G983-G989. PubMed ID: 33881350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
